Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS

ROCKVILLE, MD , Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in

ROCKVILLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the

Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a biopharmaceutical company

ROCKVILLE, MD , July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors Zai Lab provides rights to MacroGenics

Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patients Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of seven patients evaluated (including one unconfirmed partial

ROCKVILLE, MD , May 19, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in

MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing

ROCKVILLE, MD , April 19, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for

ROCKVILLE, MD , Feb. 26, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

MARGENZA™ approved in December 2020 ; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.

ROCKVILLE, MD , Feb. 18, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , Feb. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien,

ROCKVILLE, MD , Feb. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved

ROCKVILLE, MD , Feb. 08, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb)   showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® ( trastuzumab), both with chemotherapy In the U.S. , MARGENZA is approved, in combination with chemotherapy, for the treatment of

ROCKVILLE, MD , Jan. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study ROCKVILLE, MD , Dec. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based

ROCKVILLE, MD , Dec. 18, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of

53.8% ORR in relapsed/refractory DLBCL patients  Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date  ROCKVILLE, MD , Dec. 07, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company

31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients Median duration of response = 8.13 months ROCKVILLE, MD , Dec. 06, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing

MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses EVERSANA may earn revenue share payments over five years subject to predefined cap MacroGenics’ projected cash runway remains into 2023 ROCKVILLE, MD and CHICAGO, IL , Nov.